文献速递浆细胞疾病

埃罗妥珠单抗联合RVd方案治疗初治高危多发性骨髓瘤的随机Ⅱ期研究

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2020-12-22

SWOG-1211为随机Ⅱ期试验,纳入100例初治高危多发性骨髓瘤患者,比较RVd方案与RVd联合埃罗妥珠单抗方案的疗效。加用埃罗妥珠单抗未改善结局,但两组无进展生存期均超过原统计假设,支持持续蛋白酶体抑制剂联合免疫调节剂维持治疗。

要点

  • 加用埃罗妥珠单抗未改善高危多发性骨髓瘤患者的无进展生存期
  • 两组中位无进展生存期均超过原统计假设,支持持续RVd维持治疗
  • 两组3级及以上不良事件发生率相似,未见新的安全性信号

核心结论

  • 在高危多发性骨髓瘤患者中,RVd诱导及维持治疗基础上加用埃罗妥珠单抗未改善结局。
  • 两组无进展生存期均超过原统计假设,支持持续蛋白酶体抑制剂联合免疫调节剂维持治疗。

研究设计与样本

  • SWOG-1211为随机Ⅱ期试验,比较8周期RVd诱导后减量RVd维持联合或不联合埃罗妥珠单抗。
  • 2013年10月27日至2016年5月15日在美国26家合作组机构入组100例初治高危多发性骨髓瘤患者,随机1:1分组(RVd n=52,RVd-埃罗妥珠单抗 n=48)。
  • 主要终点为无进展生存期,按意向治疗在符合条件且可评估疗效的患者中分析。

主要发现

  • RVd组37例(71%)和RVd-埃罗妥珠单抗组37例(77%)发生3级及以上不良事件。
  • 3-5级感染分别为4例(8%)和8例(17%),感觉神经病变分别为4例(8%)和6例(13%),运动神经病变分别为1例(2%)和4例(8%)。
  • RVd组无治疗相关死亡,RVd-埃罗妥珠单抗组有1例死亡被研究者列为研究治疗可能相关。

关键数值与推荐

  • 高危定义包括:基因表达谱高危(GEPhi)、t(14;16)、t(14;20)、del(17p)或amp1q21、原发性浆细胞白血病及血清乳酸脱氢酶升高(≥正常上限2倍)。
  • 基线特征:中位年龄64岁(IQR 57-70,范围36-85);99例中74例(75%)为ISS Ⅱ或Ⅲ期;99例中47例(47%)有amp1q21;100例中37例(37%)有del17p。
  • 埃罗妥珠单抗10 mg/kg静脉给药:第1-2周期第1、8、15天,第3-8周期第1、11天,维持阶段第1、15天。

临床怎么用

  • 对于高危多发性骨髓瘤,RVd诱导后减量RVd持续维持治疗可获得超过原统计假设的无进展生存期。
  • 不推荐在RVd基础上常规加用埃罗妥珠单抗用于该人群。
  • 治疗期间需关注感染及神经病变等不良事件。

局限性

  • 为随机Ⅱ期试验,样本量100例,统计效能有限。
  • 主要终点分析基于可评估疗效的符合条件患者,非全部意向治疗人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of immunomodulatory agents, proteasome inhibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for patients with multiple myeloma, but patients with high-risk multiple myeloma have a poor long-term prognosis. We aimed to address optimal treatment for these patients. METHODS: SWOG-1211 is a randomised phase 2 trial comparing eight cycles of lenalidomide (25 mg orally on days 1-14 every 21 days), bortezomib (1·3 mg/m2 subcutaneously on days 1, 4, 8, and 11 every 21 days), and dexamethasone (20 mg orally on days 1, 2, 4, 5, 8, 9, 11, and 12 every 21 days; RVd) induction followed by dose-attenuated RVd maintenance (bortezomib 1 mg/m2 subcutaneously on days 1, 8, and 15; lenalidomide 15 mg orally on days 1-21; dexamethasone 12 mg orally on days 1, 18, and 15 every 28 days) until disease progression with or without elotuzumab (10 mg/kg intravenously on days 1, 8, and 15 for cycles 1-2, on days 1 and 11 for cycles 3-8, and on days 1 and 15 during maintenance). Patients were randomly assigned (1:1) to either RVd or RVd-elotuzumab. High-risk multiple myeloma was defined by one of the following: gene expression profiling high risk (GEPhi), t(14;16), t(14;20), del(17p) or amp1q21, primary plasma cell leukaemia and elevated serum lactate dehydrogenase (two times the upper limit of normal or more). The primary endpoint was progression-free survival, and all analyses were done on intention-to-treat basis among eligible patients who were evaluable for response. This study is registered with ClinicalTrials.gov, NCT01668719. FINDINGS: 100 (RVd n=52, RVd-elotuzumab n=48) patients were enrolled between Oct 27, 2013, and May 15, 2016, across 26 cooperative group institutions in the USA. Median age was 64 years (IQR 57-70, range 36-85). 74 (75%) of 99 had International Staging System stage II or stage III disease, 47 (47%) of 99 had amp1q21, 37 (37%) of 100 had del17p, 11 (11%) of 100 had t(14;16), eight (9%) of 90 were GEPhi, seven (7%) of 100 had primary plasma cell leukaemia, five (5%) of 100 had t(14;20), four (4%) of 100 had elevated serum lactate dehydrogenase, and 17 (17%) had two or more features. With a median follow-up of 53 months (IQR 46-59), no difference in median progression-free survival was observed (RVd 33·64 months [95% CI 19·55-not reached], RVd-elotuzumab 31·47 months [18·56-53·98]; hazard ratio 0·968 [80% CI 0·697-1·344]; one-sided p=0·45]. 37 (71%) of 52 patients in the RVd group and 37 (77%) of 48 in the RVd-elotuzumab group had grade 3 or worse adverse events. No significant differences in the safety profile were observed, although some notable results included grade 3-5 infections (four [8%] of 52 in the RVd group, eight [17%] of 48 in the RVd-elotuzumab group), sensory neuropathy (four [8%] of 52 in the RVd group, six [13%] of 48 in the RVd-elotuzumab group), and motor neuropathy (one [2%] of 52 in the RVd group, four [8%] of 48 in the RVd-elotuzumab group). There were no treatment-related deaths in the RVd group and one death in the RVd-elotuzumab group for which study treatment was listed as possibly contributing by the investigator. INTERPRETATION: In the first randomised study of high-risk multiple myeloma reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, progression-free survival in both study groups exceeded the original statistical assumptions and supports the role for continuous proteasome inhibitors and immunomodulatory drug combination maintenance therapy for this patient population. FUNDING: National Institutes of Health, National Cancer Institute, Bristol Myers Squibb, Celgene, Leukemia and Lymphoma Society.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2020. PMID: 33357482. doi:10.1016/S2352-3026(20)30354-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。